Hospira Issues Lidocaine Injection Recall Due to Dark Particulate Matter

Hospira Inc. has announced that it is recalling a particular lot of numbing fluid used before surgery, after confirming the presence of particulate matter in the fluid that poses a risk of inflammation, phlebitis, and occluded capillaries for patients.  

The Hospira lidocaine injection recall was announced by the FDA on October 4, after the manufacturer was able to confirm that visible particulate matter in the solutions is oxidized stainless steel, which poses an increased risk to patients receiving magnetic resonance imaging (MRI).

The recall includes Hospira Inc. 1% Lidocaine HCI Injection fluid packaged in 10 mg/mL and 20 mL Multiple-Dose Fliptop Vials with NDC number 0409-4276-01. The recalled vials have lot number 25-090-DK that may be followed by the number 01 or 02. The fluids were manufactured by Hospira Inc. and distributed from March 2013 through June 2013 to various hospitals and physicians.

Did You Know?

Millions of Philips CPAP Machines Recalled

Philips DreamStation, CPAP and BiPAP machines sold in recent years may pose a risk of cancer, lung damage and other injuries.

Learn More

Particulate matter in injection fluid can be extremely dangerous depending on the size and material of the foreign objects. Typically small particulate matter will cause phlebitis, mechanical disruption of tissue or local inflammation at the area of injection. Larger particulate matter may interfere with the injection and block the passage causing a delay in treatment. In more severe cases capillaries may become occluded and build up in the lungs.

Stainless steel particulate matter increases the risk of patients who will undergo magnetic field exposure during treatment because if the particles travel into the lungs and the magnetic resonance imaging dislodges them, it may cause hemothorax or pnemothorax, which requires significant medical intervention.

Hospira has been associated with multiple recalls over the past few years due to particulate matter contamination. Just last week Hospira issued recalls for generic Reglan and generic Zofran, after injectable versions of the drugs were found to contain strands of glass.

Earlier this year, Hospira Inc. recalled one lot of .09% sodium chloride injection following a consumer complaint indicating particulates within the fluid which after further investigation were identified in four tested samples. In September Hospira recalled a lot on Amino Acid injection fluid that was confirmed to be contaminated with human hair follicles.

Hospira recommends that those with existing inventory stop using it immediately, quarantine the product, and contact Stericycle at 1-866-364-8812 to arrange a return and replacement of the product. Clinical inquiries should be directed to either Hospira Global Complaint Manager at 1-800-441-4100 or Hospira Medical Communications at 1-800-615-0187.


"*" indicates required fields

Share Your Comments

I authorize the above comments be posted on this page*

Have Your Comments Reviewed by a Lawyer

Provide additional contact information if you want an attorney to review your comments and contact you about a potential case. This information will not be published.

NOTE: Providing information for review by an attorney does not form an attorney-client relationship.

This field is for validation purposes and should be left unchanged.

More Top Stories

Bard 3DMax Hernia Mesh Lawsuit Set for Trial To Begin in April 2024
Bard 3DMax Hernia Mesh Lawsuit Set for Trial To Begin in April 2024 (Posted yesterday)

With thousands of Bard hernia mesh lawsuits pending in the federal court system, a fourth bellwether trial will be held in the spring, involving allegations that defects with Bard 3DMax caused painful and permanent injuries.

Ozempic Gastroparesis Lawsuit Filed Over Failure To Warn About Permanent Stomach Problems
Ozempic Gastroparesis Lawsuit Filed Over Failure To Warn About Permanent Stomach Problems (Posted 3 days ago)

A South Dakota man has filed one of the first gastroparesis lawsuits against Ozempic manufacturers, alleging that users have not been adequately warned about the risk of severe vomiting and long-term stomach side effects.